| Mechanisms of red blood cell transfusion-related immunomodulation |
27 |
| Inactivation of Ebola virus and Middle East respiratory syndrome coronavirus in platelet concentrates and plasma by ultraviolet C light and methylene blue plus visible light, respectively |
26 |
| Clinical outcomes among low-titer group O whole blood recipients compared to recipients of conventional components in civilian trauma resuscitation |
21 |
| Give the trauma patient what they bleed, when and where they need it: establishing a comprehensive regional system of resuscitation based on patient need utilizing cold-stored, low-titer O plus whole blood |
18 |
| Methylation of protein aspartates and deamidated asparagines as a function of blood bank storage and oxidative stress in human red blood cells |
17 |
| Safety profile of uncrossmatched, cold-stored, low-titer, group O plus whole blood in civilian trauma patients |
17 |
| Addressing gaps in international blood availability and transfusion safety in low- and middle-income countries: a NHLBI workshop |
16 |
| Heterogeneity of blood processing and storage additives in different centers impacts stored red blood cell metabolism as much as storage time: lessons from REDS-III-Omics |
15 |
| Lymphocyte apheresis for chimeric antigen receptor T-cell manufacturing in children and young adults with leukemia and neuroblastoma |
14 |
| Inactivation of Middle East respiratory syndrome-coronavirus in human plasma using amotosalen and ultraviolet A light |
13 |
| Accurate costs of blood transfusion: a microcosting of administering blood products in the United Kingdom National Health Service |
13 |
| Therapeutic use of mesenchymal stem cell-derived extracellular vesicles in acute lung injury |
13 |
| Chronological storage age and metabolic age of stored red blood cells: are they the same? |
13 |
| Elevated risk for iron depletion in high-school age blood donors |
13 |
| The effects of monoclonal anti-CD47 on RBCs, compatibility testing, and transfusion requirements in refractory acute myeloid leukemia |
12 |
| Safety and efficacy of cryopreserved platelets in bleeding patients with thrombocytopenia |
12 |
| A randomized, controlled pilot clinical trial of cryopreserved platelets for perioperative surgical bleeding: the CLIP-I trial |
12 |
| Platelet-derived extracellular vesicles convey mitochondrial DAMPs in platelet concentrates and their levels are associated with adverse reactions |
12 |
| Systematic review of rituximab for autoimmune diseases: a potential alternative to intravenous immune globulin |
11 |
| The effect of therapeutic leukapheresis on early complications and outcomes in patients with acute leukemia and hyperleukocytosis: a propensity score-matched study |
11 |
| Usutu virus infection in Dutch blood donors |
11 |
| Characterization and cost-benefit analysis of automated bioreactor-expanded mesenchymal stem cells for clinical applications |
11 |
| Outcomes of traumatic hemorrhagic shock and the epidemiology of preventable death from injury |
10 |
| Modifiers of mesenchymal stem cell quantity and quality |
10 |
| Implementation of secondary bacterial culture testing of platelets to mitigate residual risk of septic transfusion reactions |
10 |
| How do I implement a whole blood program for massively bleeding patients? |
10 |
| Compliance with time-based deferrals for men who have sex with men |
10 |
| Intradonor reproducibility and changes in hemolytic variables during red blood cell storage: results of recall phase of the REDS-III RBC-Omics study |
10 |
| Platelet enhancement of bacterial growth during room temperature storage: mitigation through refrigeration |
10 |
| The use of cryopreserved platelets in the treatment of polytraumatic patients and patients with massive bleeding |
10 |
| Red blood cell specifications for patients with hemoglobinopathies: a systematic review and guideline |
10 |
| Effective inactivation of a wide range of viruses by pasteurization |
10 |
| A systematic review of incentives in blood donation |
10 |
| Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026) |
9 |
| Assessment of HIV transfusion transmission risk in South Africa: a 10-year analysis following implementation of individual donation nucleic acid amplification technology testing and donor demographics eligibility changes |
9 |
| Safety evaluation of a lyophilized platelet-derived hemostatic product |
9 |
| Blood transfusion safety in sub-Saharan Africa: a literature review of changes and challenges in the 21st century |
9 |
| Analysis of pediatric adverse reactions to transfusions |
9 |
| Comparison between manufacturing sites shows differential adhesion, activation, and GPIb alpha expression of cryopreserved platelets |
9 |
| Bags versus flasks: a comparison of cell culture systems for the production of dendritic cell-based immunotherapies |
9 |
| Automated typing of red blood cell and platelet antigens from whole exome sequences |
9 |
| Factors affecting lymphocyte collection efficiency for the manufacture of chimeric antigen receptor T cells in adults with B-cell malignancies |
9 |
| Metabolic effect of alkaline additives and guanosine/gluconate in storage solutions for red blood cells |
9 |
| Use of intravenous immunoglobulin G to treat spontaneous heparin-induced thrombocytopenia |
9 |
| Electronic patient identification for sample labeling reduces wrong blood in tube errors |
9 |
| The use of whole blood in US military operations in Iraq, Syria, and Afghanistan since the introduction of low-titer Type O whole blood: feasibility, acceptability, challenges |
9 |
| Monoclonal anti-CD47 interference in red cell and platelet testing |
9 |
| Effect of leukoreduction and pathogen reduction on the hemostatic function of whole blood |
9 |
| Improving quality of care for patients with iron deficiency anemia presenting to the emergency department |
9 |
| Characterization of biologic response modifiers in the supernatant of conventional, refrigerated, and cryopreserved platelets |
9 |
